NCT06493461View on ClinicalTrials.gov

A Study of HS135 for the Treatment of Pulmonary Arterial Hypertension in Adults

PHASE1TerminatedINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

October 23, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions

Pulmonary Arterial Hypertension (PAH)

Interventions

BIOLOGICAL

HS135

HS135 is dosed subcutaneously

Trial Locations (2)

17475

Site-202, Greifswald

T6G 2C8

Site-501, Edmonton

Sponsors

Lead Sponsor

All Listed Sponsors

lead

35Pharma Inc

INDUSTRY